Результаты поиска - Yunling Du

  • Отображение 1 - 12 результаты of 12
Отмена результатов
  1. 1
    Plus disease in retinopathy of prematurity: Pilot study of computer-based and expert diagnosis

    Plus disease in retinopathy of prematurity: Pilot study of computer-based and expert diagnosis по Rony Gelman, Lei Jiang, Yunling Du, M. Elena Martínez-Pérez, John T. Flynn, Michael F. Chiang

    Опубликовано 2007
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  2. 2
    Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the <scp>ODYSSEY OPTIONS</scp> Studies

    Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosu... по Jennifer G. Robinson, Helen M. Colhoun, Harold Bays, Peter H. Jones, Yunling Du, Corinne Hanotin, Stephen Donahue

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Effect of Cisternal and Ventricular Blood on Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage:

    Effect of Cisternal and Ventricular Blood on Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: по Jan Claassen, Gary L. Bernardini, Kurt T. Kreiter, Joseph E Bates, Yunling Du, Daphne Copeland, E. Sander Connolly, Stephan A. Mayer

    Опубликовано 2001
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  4. 4
    Effects of a School-based Intervention for Urban Adolescents with Asthma

    Effects of a School-based Intervention for Urban Adolescents with Asthma по Jean‐Marie Bruzzese, Beverley J. Sheares, Elisa J. Vincent, Yunling Du, Hossein Sadeghi, Moshe J. Levison, Robert B. Mellins, David J Evans

    Опубликовано 2010
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II rand... по Michel Farnier, Peter J.H. Jones, Randall Severance, Maurizio Averna, Elisabeth Steinhagen‐Thiessen, Helen M. Colhoun, Yunling Du, Corinne Hanotin, Stephen Donahue

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  6. 6
    Remote image based retinopathy of prematurity diagnosis: a receiver operating characteristic analysis of accuracy

    Remote image based retinopathy of prematurity diagnosis: a receiver operating characteristic analysis of accuracy по Michael F. Chiang, Justin Starren, Yunling Du, Jeremy D. Keenan, William M. Schiff, Gaetano R. Barile, Joan Li, Rose Johnson, Ditte J. Hess, John T. Flynn

    Опубликовано 2006
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Subthalamic stimulation for Parkinson disease: determination of electrode location necessary for clinical efficacy

    Subthalamic stimulation for Parkinson disease: determination of electrode location necessary for clinical efficacy по Shearwood McClelland, Blair Ford, Patrick B. Senatus, Linda Winfield, Yunling Du, Seth L. Pullman, Qiping Yu, Steven J. Frucht, Guy M. McKhann, Robert Goodman

    Опубликовано 2005
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

    Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phas... по Daniel Gaudet, Dean J. Kereiakes, James M. McKenney, Eli M. Roth, Corinne Hanotin, Daniel A. Gipe, Yunling Du, Anne-Catherine Ferrand, Henry N. Ginsberg, Evan A. Stein

    Опубликовано 2014
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

    Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol по Evan A. Stein, Scott Mellis, George D. Yancopoulos, Neil Stahl, Douglas Logan, William Smith, Eleanor Lisbon, María J. Gutiérrez, Cheryle Webb, Richard Wu, Yunling Du, Therese Kranz, Evelyn Gasparino, Gary D. Swergold

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

    Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial по Patrick M. Moriarty, Paul D. Thompson, Christopher P. Cannon, John R. Guyton, Jean Bergeron, Franklin J. Zieve, Éric Bruckert, Terry A. Jacobson, Stephen L. Kopecky, Marie T. Baccara‐Dinet, Yunling Du, Robert Pordy, Daniel A. Gipe

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

    Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial по Patrick M. Moriarty, Klaus G. Parhofer, Stephan P. Babirak, Marc-Andre Cornier, P. Barton Duell, Bernd Hohenstein, Josef Leebmann, Wolfgang Ramlow, Volker Schettler, Vinaya Simha, Elisabeth Steinhagen‐Thiessen, Paul D. Thompson, Anja Vogt, Berndt von Stritzky, Yunling Du, Garen Manvelian

    Опубликовано 2016
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Characterization of Autosomal Dominant Hypercholesterolemia Caused by <i>PCSK9</i> Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody

    Characterization of Autosomal Dominant Hypercholesterolemia Caused by <i>PCSK9</i> Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibod... по Paul N. Hopkins, Joep C. Defesche, Sigrid W. Fouchier, Éric Bruckert, Gérald Luc, Bertrand Cariou, Barbara Sjouke, Trond P. Leren, Mariko Harada‐Shiba, Hiroshi Mabuchi, Jean‐Pierre Rabès, Alain Carrié, Charles van Heyningen, Valérie Carreau, Michel Farnier, Yee Ping Teoh, Mafalda Bourbon, Masa-aki Kawashiri, Atsushi Nohara, Handrean Soran, A. David Marais, Hayato Tada, Marianne Abifadel, Cathérine Boileau, B. Chanu, Shoji Katsuda, Ichiro Kishimoto, Gilles Lambert, Hisashi Makino, Yoshihiro Miyamoto, Matthieu Pichelin, Kunimasa Yagi, Masakazu Yamagishi, Yassine Zaïr, Scott Mellis, George D. Yancopoulos, Neil Stahl, Johanna Mendoza, Yunling Du, Sara Hamon, Michel Krempf, Gary D. Swergold

    Опубликовано 2015
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: